Anzupgo LEO Pharma A/S · Authorised · authorised 19 Sep 2024 · ATC D11AH11
Therapeutic indication (EMA)
Anzupgo is indicated for the treatment of moderate to severe chronic hand eczema (CHE)
Active substance
Delgocitinib
- US FDA 1
- EMA 1
- Health Canada 1
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ANZUPGO | 2% | cream · topical | LEO PHARMA AS | Prescription | 23 Jul 2025 |
EMA European Union — centrally authorised medicines
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ANZUPGO | 02560704 | 20 MG / G | CREAM · TOPICAL | LEO PHARMA INC |
Safety signals and safety-related labeling changes
- US FDA 30 Jun 2026 ANZUPGO — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.